Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.57 |
| ▸ | BCHE | P06276 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14424032 | 0.85 | ACHE (0.53) | ACHEBCHEALDH1A1TSHRGFER | |
| SCHEMBL2342398 | 0.82 | ACHE (0.51) | ACHEBCHEKDM4EALDH1A1TSHR | |
| SCHEMBL5593151 | 0.80 | ACHE (0.68) | ACHEBCHEKDM4EALDH1A1HRH3 | |
| SCHEMBL15499985 | 0.76 | KDM4E (0.58) | KDM4EALDH1A1TSHR | |
| SCHEMBL2014741 | 0.75 | KDM4E (0.61) | ACHEBCHEKDM4EALDH1A1GFER | |
| SCHEMBL2483662 | 0.75 | ACHE (0.51) | ACHEBCHEKDM4EALDH1A1CACNA1B | |
| SCHEMBL2486252 | 0.75 | ACHE (0.51) | ACHEBCHEKDM4EALDH1A1CACNA1B | |
| SCHEMBL13339343 | 0.75 | ACHE (0.51) | ACHEBCHEKDM4EALDH1A1CACNA1B | |
| SCHEMBL14423575 | 0.74 | ACHE (0.54) | ACHEBCHEKDM4EALDH1A1CACNA1B | |
| SCHEMBL2487271 | 0.74 | ACHE (0.52) | ACHEBCHEKDM4EALDH1A1CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130035349-A1 | PYRAZOLOPYRIMIDINONE KINASE INHIBITOR | AGENNIX AG (DE) | 2013-02-07 | — | — | US | disclosed |
| US-8304418-B2 | Pyrazolopyrimidinone kinase inhibitor | AGENNIX AG (DE) | 2012-11-06 | — | — | US | disclosed |
| US-20100160350-A1 | PYRAZOLOPYRIMIDINONE KINASE INHIBITOR | AGENNIX AG (DE) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035349-A1 | PYRAZOLOPYRIMIDINONE KINASE INHIBITOR | MAP3K19, MAP3K4, MAP3K1 | ACHE 4863/4885BCHE 4845/4885KDM4E 870/4885 |
| US-20100160350-A1 | PYRAZOLOPYRIMIDINONE KINASE INHIBITOR | MAP3K19, MAP3K4, MAP3K1 | ACHE 4863/4885BCHE 4845/4885KDM4E 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.